Canine Parvo virus is a deadly virus with high mortality. The available vaccine is not effective due to antigenic drift and continuous mutations of virus and vaccine are made on isolates from non-Indian isolates. Therefore there is a need for alternative ways to treat this viral disease where there are several antigenic drifts reported with Indian isolates. NANOGLOB-P is developed with chicken IgY antibodies against Indian isolate of Canine Parvo virus. These antibodies are known to neutralize virus and protect dog from deadly virus. Specialized antibodies to parvo virus infection from Indian isolates provides better protection.

Description

Canine parvovirus infection occurs worldwide in domestic dogs and other members of the dog family. Incidence is higher in animal shelters, pet stores, and breeding kennels. CPV can affect dogs at any age. Severe infection is most common in puppies between 6 weeks and 4 months old. All breeds of dogs are susceptible. The CPV infection is more severe in young puppies especially those younger than 3 months of age. All infected dogs may not necessarily exhibit clinical manifestations but they may shed the virus in feces during the acute phase of enteric fever. CPV has high morbidity (100%) and frequent mortality upto 10% in adult dogs and 91% in pups. Based on VP2 gene sequences, it is revealed that the Indian isolates formed a separate lineage distinct from the South East Asian isolates and the canine parvovirus isolates in India appear to have evolved independently without any distinct geographical patterns of evolution.

‘Parvo’ means small (Latin), canine parvovirus belongs to genus Parvovirus and family Parvoviridae. The genome is a single stranded negative sense DNA having size of 5.2 Kb in length which has two promoters resulting in the expression of three structural (VP1, VP2 and VP3) and two non- structural proteins (NS1 and NS2) through alternate splicing of the viral mRNAs. VP2 (64 kDa) is an NH2- terminally truncated form of VP1 (84 kDa) and is the major component of the capsid. VP3 is derived from VP2 by posttranslational proteolytic cleavage and is present only in complete (DNA containing) virions. VP2, is the major structural protein in most parvovirus that comprises about 90% of the capsid.

Canine parvovirus (CPV) is the most significant viral cause of acute haemorrhagic enteritis and myocarditis in puppies over the age of 3-4 months. There is enough indication of circulation of new CPV-2b strain from different states of Southern India. As the CPV strains were found to be under immense selection pressure and realizing the constant mutations happening in the field strains. Only one CPV-2b based vaccine is available. The available vaccine is not effective due to antigenic drift and continuous mutations of virus and vaccine are made on isolates from non-Indian isolates. Therefore there is a need for alternative ways to treat this viral disease where there are several antigenic drifts reported with Indian isolates.

Egg yolk immunoglobulin produced from chicken also known as IgY is a passive, inexpensive and easy to produce immunoglobulin which is produced in a natural way from immunized birds. It has attracted much attention to be efficient in therapy and prevention, reported in oral administration of polyclonal IgY immunoglobulins. IgY is experiencing high interest mainly due to the high specificity, strong avidity and low production costs of as compared to mammalian antibodies.  Biologically active IgY immunoglobulins are transmitted vertically from blood into the egg yolk and can be extracted easily from the egg yolk.  Antibody therapy neutralizes CPV2, a causative agent, present in the gut of an infected pups and dogs. The binding of IgY to virus causes trapping of virus, which may impede the adhesion of virus to intestinal epithelial cells. Neutralization of antibody therapies has not been reported for resistance so far. A unique approach to neutralize virus and curb viral growth via neutralization by IgY antibodies is a novel approach to improve the health of infected pups and dogs along with a supportive therapy.

Components

Canine parvovirus is a contagious virus mainly affecting dogs. CPV is highly contagious and is spread from dog to dog by direct or indirect contact with their feces. Parvo in puppies is caused by the canine parvovirus. This virus is highly contagious and spreads through direct contact with an infected dog or by indirect contact with a contaminated object. Your puppy is exposed to the parvovirus every time he sniffs, licks, or consumes infected feces. The virus weakens the body’s ability to protect itself by destroying young immune cells and causing a drop in the protective white blood cell count.

IgY antibodies possess the ability to decrease the potency of the virus thereby reducing its ability to infect host cells as well as suppress the spread of infection and even prevent death.

NANOGLOB-P is developed with chicken IgY antibodies against Indian isolate of Canine Parvo virus. The antibodies are packed in injection vial and stored at 4-8C. These antibodies has high virus neutralizing ability of parvo virus infections.

Hyperimmune IgY antibodies raised in chicken. Each vial contain antibodies at 5mg/ml concentration.

Benefits

IgY antibodies against parvo virus neutralizes.

Alternate treatment in parallel as supportive fluid therapy, antibiotics, and vitamins

Dosage

1 ml for 2 kg body weight

Usage instruction

Keep injection vial at 4-8C and inject antibodies at dose of 0.5ml / kg body weight. The antibodies should be used I/V with IV fluid.